Physician profile
Howard Rothman
NPI 1134125941
$3,193.17
in general payments reported to CMS, 2019-2025
39 companies · $333 in 2025
The $333 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $167 · 2021: $848 · 2022: $491 · 2023: $246 · 2024: $477 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $337.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $231.14 | 2019-2025 | |
| Pfizer INC. | $191.37 | 2019-2025 | |
| Cvrx, INC. | $189.82 | 2024 | Barostim Neo System |
| Amarin Pharma, INC. | $166.41 | 2019-2022 | |
| Novo Nordisk INC | $155.40 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $153.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.84 | 2019-2024 | Ofev |
| Merck Sharp & Dohme LLC | $128.68 | 2024-2025 | Verquvo, Capvaxive |
| Vifor Pharma, INC. | $128.35 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals Lp | $107.64 | 2019-2025 | Farxiga |
| Lundbeck LLC | $103.34 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $102.96 | 2019-2023 | Camzyos |
| Boston Scientific Corporation | $100.87 | 2021-2023 | Watchman Access System |
| Baxter Healthcare | $92.30 | 2025 | Hillrom - Carnation Ambulatory Monitor |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Rothman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.